公开(公告)号：EP2019147B1

公开(公告)日：2011-05-04

申请号：EP06732665.2

申请日：2006-05-16

申请人： THE KITASATO INSTITUTE

发明人： TOMODA, Hiroshi ,  KIM, Yong-pil ,  HANAKI, Hideaki ,  MATSUMOTO, Atsuko ,  TAKAHASHI, Yoko ,  OMURA, Satoshi

IPC分类号： C12P19/26 ,  C07H11/04 ,  A61K31/7024 ,  A61P31/04

CPC分类号： C07H11/04 ,  C07C323/59 ,  C12P13/02 ,  C12P19/26 ,  C12P19/44 ,  C12R1/465

摘要： K04-0144 substances A, B and C which can be produced by culturing a microorganism exemplified by Streptomyces sp. strain K04-0144 (which is capable of producing K04-0144 substances) in a culture medium and then collecting the substances from the culture medium. The substances have a potent antibacterial activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and are therefore useful as therapeutic agents for MRSA infection and infectious diseases caused by multidrug-resistant bacteria including β-lactam antibiotic-resistant bacteria. A novel K04-0144 substance D which is also collected from the culture medium can enhance the effect of a β-lactam antibiotic (which has been used as an antibacterial agent) by using it in combination with the β-lactam antibiotic, and is therefore useful as a therapeutic agent for methicillin-resistant Staphylococcus aureus (MRSA) infection and infectious diseases caused by multidrug-resistant bacteria including β-lactam antibiotic-resistant bacteria.

公开(公告)号：EP2019147A1

公开(公告)日：2009-01-28

申请号：EP06732665.2

申请日：2006-05-16

申请人： THE KITASATO INSTITUTE

发明人： TOMODA, Hiroshi ,  KIM, Yong-pil ,  HANAKI, Hideaki ,  MATSUMOTO, Atsuko ,  TAKAHASHI, Yoko ,  OMURA, Satoshi

IPC分类号： C12P19/26 ,  C07H11/04 ,  A61K31/7024 ,  A61P31/04

CPC分类号： C07H11/04 ,  C07C323/59 ,  C12P13/02 ,  C12P19/26 ,  C12P19/44 ,  C12R1/465

摘要： Amicroorganism represented by a strain K04-0144 belonging to Streptomyces sp. having ability to produce K04-0144 substance is cultured in the medium, and the isolated K04-0144A substance, K04-0144B substance and K04-0144C substance therefrom have strong antibacterial activities against Gram-positive bacteria including methicillin-resistant Streptococcus aureus (MRSA), consequently these are useful as the therapeutic agents for infectious disease caused by MRSA as well as infectious diseases caused by multidrug including β-lactam antibiotics resistant bacteria. Further, similarly, since the novel K04-0144D substance isolated from the cultured liquid has the action for enhancing the effect of β-lactam antibiotics, which are utilized as the antibacterial agents, in combination with them, it is useful as the therapeutic agent for infectious diseases caused by methicillin-resistant Staphylococcus aureus (MRSA) and multidrug including β-lactam antibiotics resistant bacteria.

摘要翻译： 由属于链霉菌属的菌株K04-0144代表的微生物。 在培养基中培养具有产生K04-0144物质的能力，并且分离出的K04-0144A物质，K04-0144B物质和K04-0144C物质对包括耐甲氧西林金黄色葡萄球菌（MRSA）在内的革兰氏阳性菌具有强的抗菌活性， 因此它们可用作由MRSA引起的感染性疾病的治疗剂以及由包括β-内酰胺抗生素抗性细菌在内的多种药物引起的感染性疾病。 此外，类似地，由于从培养液中分离出的新型K04-0144D物质具有提高作为抗菌剂使用的β-内酰胺抗生素的效果的作用，因此与它们组合使用时，可用作 由耐甲氧西林金黄色葡萄球菌（MRSA）引起的传染病和包括β-内酰胺抗生素耐药细菌在内的多种药物。